Global Cancer Diagnostics Market is Poised to Grow at 11.7% till 2024

Global  Cancer Diagnostics Market By Technology {ELISA, ELFA, PCR, NGS, Immunohistochemistry, Microarray, Imaging (MRI, CT, PET, Ultrasound, Mammography), Biopsy} Application (Breast Cancer, Lung Cancer, Colorectal Cancer, Melanoma) Geography (North America, Europe, APAC, South America, Rest of the World) – Trends and Forecast to 2024 ”,is projected to reach USD 18.4 billion by 2024 from USD 7.6 billion in 2016, at a CAGR of 11.7% in the forecast period 2017 to 2024. Access Full Report: https://www.databridgemarketresearch.com/reports/global-cancer-diagnostics-market The new market report contains data for historic year 2015, the base year of calculation is 2016 and the forecast period is 2017 to 2024. Cancer is defined as a malignant growth or tumor resulting from an uncontrolled division of cells. According to Centers for Disease Control and Prevention (CDC), cancer is the second leading cause of mortality, causing approximately 584,881 deaths worldwide in 2013. Early diagnosis is the key to prevent the rising number of cancer-related deaths. The global cancer diagnostics market is witnessing a rapid transformation owing to several technological advancements in diagnostic platforms such as next-generation sequencing, DNA microarrays, and polymerase chain reaction (PCR), among others. Moreover, the market has seen the advent of hybrid imaging instruments with enhanced accuracy, such as PET/CT and SPECT/CT. These advancements have augmented the growth of the cancer diagnostics market.

Market Segmentation: Cancer Diagnostics Market

• The Cancer Diagnostics Market is segmented on the basis of technology  and application.
• The Global Cancer Diagnostics Market, by technology, is categorized into two main segments—platform based and instrument-based. Platform-based segment is further segmented into Polymerase Chain Reaction (PCR), In Situ Hybridization (ISH), Immunohistochemistry (IHC), Next-Generation Sequencing (NGS), DNA Microarrays, Flow Cytometry and other technologies. Instrument-based segment is further segmented into Imaging (Magnetic Resonance Imaging (MRI), Computed Tomography (CT), Positron Emission Tomography (PET), mammography, and ultrasound), and Biopsy.
• The global cancer diagnostics market is segmented based on application into lung cancer, breast cancer, colorectal cancer, melanoma and other forms of cancer. Breast cancer diagnosis is expected to hold the largest share of this market in 2015, due to its high prevalence in North America also due to high expense of mammography instruments.

Geographical Segmentation: Cancer Diagnostics Market

Based on geography the global cancer diagnostics market  covers data points for 52 countries across multiple geographies namely North & South America, Europe, Asia-Pacific and, Middle East & Africa. Some of the major countries covered in this report are U.S., Germany, France, U.K., Netherlands, Switzerland, Turkey, Russia, China, India, South Korea, Japan, Australia, Singapore, Saudi Arabia, South Africa, and Brazil among others. North America holds the largest market followed by Asia Pacific which is growing rapidly. Brazil and Middle East are among the others geographies growing prolifically. North America dominates the market in terms of consumption of hemostats followed by Europe and APAC.

Competitive Landscape: Cancer Diagnostics Market

The global cancer diagnostics market is highly fragmented with various companies operating in local regions. The major players have used various strategies such as new product launches, expansions, agreements, joint ventures, partnerships, acquisitions, and others to increase their footprints in this market.The global cancer diagnostics market report contains an in-depth profiling of the key market players, along with the recent developments (new product launches, partnerships, agreements, collaborations, and joint ventures) and strategies adopted by them to sustain and strengthen their position in the market. Some of the major players operating in this market are Abbott Laboratories, Inc., Thermo Fisher Scientific, Inc., Illumina, Inc., Becton, Dickinson and Company, General Electric Company, QIAGEN N.V., Agilent Technologies, Inc., Hoffmann-La Roche Ltd., Siemens Healthcare GmbH, Koninklijke Philips N.V., and C.R. Bard, Inc., Hologic, Inc. among other players. Global Bioburden Testing Market, By Test Type (Aerobic, Anaerobic, Fungi, Spore), By Product Type (Instruments (PCR, Automated Microbial Identification Systems, Microscopes, Others), Consumables (Kits & Strips, Reagents, Others), By Technology (Microbial Filter Method, Advanced Colorimetric Method, Plate Count Method, Rapid Testing), By Application (Raw Material Testing, In-Process Testing, Medical Device Testing, Pharmaceutical & Cosmetic Testing, Food and Beverage Testing), By End-User (Pharmaceutical, Biotechnology, Industrial, Food & Beverages), By Geography (North America, Europe, Asia-Pacific, South America and Middle East Asia) – Industry Trends and Forecast to 2024